ライフサイエンスコーパス: insulin sensitivity

1 lved in the regulation of glucose uptake and insulin sensitivity.

2 that bridges WAT inflammation to whole-body insulin sensitivity.

3 ively associated with hepatic and whole-body insulin sensitivity.

4 omeostasis by modulating insulin levels, not insulin sensitivity.

5 ydrophobic motif site that is a biomarker of insulin sensitivity.

6 ver specific lipids that most heavily impact insulin sensitivity.

7 d ultimately contributes to impaired hepatic insulin sensitivity.

8 with markers of metabolic health, including insulin sensitivity.

9 fits mediated by improvements in endothelial insulin sensitivity.

10 metabolism and the long-term improvement of insulin sensitivity.

11 thereby improving adipose tissue and hepatic insulin sensitivity.

12 with low insulin concentrations and greater insulin sensitivity.

13 drial function in offspring without changing insulin sensitivity.

14 ed metabolic indices, including promotion of insulin sensitivity.

15 porters in the small intestine and improving insulin sensitivity.

16 either glucose-induced insulin secretion or insulin sensitivity.

17 mia-was significantly associated with muscle insulin sensitivity.

18 metabolic regeneration of liver function and insulin sensitivity.

19 exhibited an improved glucose tolerance and insulin sensitivity.

20 caused significant (P = 0.014) impairment in insulin sensitivity.

21 of the adipose-secreted hormone, leptin, on insulin sensitivity.

22 on in prediabetic rats without alteration in insulin sensitivity.

23 lin secretion and degradation, and increases insulin sensitivity.

24 n is secreted by adipose tissue and promotes insulin sensitivity.

25 creased muscle glucose uptake and whole-body insulin sensitivity.

26 that DEP exposure primarily targeted hepatic insulin sensitivity.

27 augmented whole-body energy expenditure and insulin sensitivity.

28 from adipose tissue, is expected to promote insulin sensitivity.

29 selectively in skeletal muscle have improved insulin sensitivity.

30 administration decreases TAZ, IRS1 level and insulin sensitivity.

31 lts suggest that nut consumption may improve insulin sensitivity.

32 itivity and couples Hippo/Wnt signalling and insulin sensitivity.

33 cated improvements in both adipose and liver insulin sensitivity.

34 impaired metabolism together with decreased insulin sensitivity.

35 significantly decreased Irs1 expression and insulin sensitivity.

36 ng that it interacts with TMEM127 to control insulin sensitivity.

37 t to hepatic and peripheral clearance or for insulin sensitivity.

38 creased LDL-cholesterol level, and decreased insulin sensitivity.

39 is, accompanies the lack of rapid changes in insulin sensitivity.

40 of type 2 diabetes through an impairment of insulin sensitivity.

41 d energy expenditure, glucose tolerance, and insulin sensitivity.

42 wer intake of BCAAs improves tissue-specific insulin sensitivity.

43 skeletal muscle and perirenal fat, favouring insulin sensitivity.

44 rgeting this feedback inhibition can improve insulin sensitivity.

45 rmine the mechanisms by which PAHSAs improve insulin sensitivity.

46 resulting in impaired glucose tolerance and insulin sensitivity.

47 the S6K1 inhibitor PF-4708671 (PF) increases insulin sensitivity.

48 and maximal C-peptide responses adjusted for insulin sensitivity.

49 ation, including IL1beta levels and improves insulin sensitivity.

50 trial of the effect of coffee consumption on insulin sensitivity.

51 d glucose and pyruvate tolerance, but normal insulin sensitivity.

52 s of dietary protein restriction to increase insulin sensitivity.

53 d hepatic steatosis, significantly improving insulin sensitivity.

54 -h ambulatory blood pressure monitoring, and insulin sensitivity.

55 aintenance of normal glucose homeostasis and insulin sensitivity.

56 w STAT1 activity in white adipocytes affects insulin sensitivity.

57 ccompanying by reduced obesity, and improved insulin sensitivity.

58 ice displayed glucose intolerance but normal insulin sensitivity.

59 ved glucose tolerance, and improved systemic insulin sensitivity.

60 53%) had pre-diabetes and 92% a reduction in insulin sensitivity.

61 ss and adiposity, as well as disturbances of insulin sensitivity.

62 ce the relationship between these lipids and insulin sensitivity.

63 glucose concentration and in improvements in insulin sensitivity.

64 shed markers of metabolic disease, including insulin sensitivity.

65 s, central and systemic blood pressure (BP), insulin sensitivity (1/fasting insulin concentration), f

66 auer recovery and adult lifespan by altering insulin sensitivity according to the prevailing insulin

67 signaling through TBC1D4 to enhanced muscle insulin sensitivity after activation of the cellular ene

68 Exercise-induced increases in insulin sensitivity after bariatric surgery are at least

69 The mechanisms underlying improved insulin sensitivity after surgically-induced weight loss

70 owering glucose homeostasis and/or improving insulin sensitivity after treatment with thiazolidinedio

71 with reduced hepatic steatosis and improved insulin sensitivity, albeit with a possible modest defec

72 ly reduces hypertriglyceridemia and improves insulin sensitivity along with beta-cell function by red

73 e-body glucose clearance and skeletal muscle insulin sensitivity along with enhanced autophagy (incre

74 relating the amount of insulin secreted for insulin sensitivity also improved (P = 0.04).

75 atterns that potentially allow for increased insulin sensitivity and a higher expression of genes in

76 strongest individual predictor of whole-body insulin sensitivity and also a marker of visceral and ec

77 vo non-invasive chronic NMES on muscle mass, insulin sensitivity and arterial blood pressure (BP).

78 ng antibodies targeting serum FABP4 increase insulin sensitivity and attenuate hepatic glucose output

79 iver fat content, and it improves multiorgan insulin sensitivity and beta-cell function (i.e., it ben

80 ty and type 2 diabetes, weight loss improves insulin sensitivity and beta-cell function, and can indu

81 Both groups showed similar levels of insulin sensitivity and beta-cell function.

82 ntrols; both groups showed similar levels of insulin sensitivity and beta-cell function.

83 insulin signalling activator that increases insulin sensitivity and couples Hippo/Wnt signalling and

84 take increases energy expenditure, increases insulin sensitivity and decreases body weight in rodents

85 e was six-month change in insulin secretion, insulin sensitivity and disposition index.

86 improved glucose tolerance, despite impaired insulin sensitivity and enhanced pyruvate-mediated gluco

87 though long-term endurance exercise promotes insulin sensitivity and expands respiratory capacity, ge

88 /kg body weight, improves glucose tolerance, insulin sensitivity and fasting blood glucose in diet-in

89 olic profile that correlates with heightened insulin sensitivity and GLP-1 secretion.

90 at a lead compound from this series improves insulin sensitivity and glucose control in the diet-indu

91 Insulin sensitivity and glucose disappearance rate were

92 an NAD(+) dependant deacetylase, in improved insulin sensitivity and glucose homeostasis, linking hyp

93 r and skeletal muscle and exhibited improved insulin sensitivity and glucose tolerance.

94 /flin) ; Adipo-Cre (+/-) ) restores systemic insulin sensitivity and glucose tolerance.

95 They markedly improved muscle insulin sensitivity and glucose uptake, and decrease ant

96 tformin effects result in the improvement of insulin sensitivity and glucose utilization in extrahepa

97 t mice exhibit reduced glucose tolerance and insulin sensitivity and have lower maximal oxygen consum

98 -living conditions, eTRF improves whole-body insulin sensitivity and increases skeletal muscle glucos

99 se tolerance test were performed to evaluate insulin sensitivity and insulin kinetics after glucose i

100 Plasma glucose, insulin sensitivity and insulin secretion were also comp

101 ytic isoform of PI3K in muscle in control of insulin sensitivity and muscle mass, and has a unique ro

102 differential DNA methylation (DNAm) controls insulin sensitivity and obesity by modulating transcript

103 ive genes in the intestinal ileum to augment insulin sensitivity and of cholesterol transport genes i

104 Depletion of GRB10 increases insulin sensitivity and overexpression suppresses PI3K/A

105 In LCSFA-HFD, whole-body insulin sensitivity and peripheral insulin-stimulated gl

106 e investigated associations between maternal insulin sensitivity and placental DNA methylation marker

107 SG improved insulin sensitivity and reduced hepatic and monocyte fat

108 Premenopausal women exhibit enhanced insulin sensitivity and reduced incidence of type 2 diab

109 Meanwhile, an NRTI, lamivudine, improves insulin sensitivity and reduces inflammasome activation

110 fects of gastric sleeve surgery in improving insulin sensitivity and reducing insulin demand.

111 21), a hepatokine known to increase systemic insulin sensitivity and regulate whole-body lipid metabo

112 ed gene expressions, fasting glucose levels, insulin sensitivity and restored pancreatic islet cell m

113 content and visceral adipose tissue, greater insulin sensitivity and secretion, greater cardiorespira

114 ession of the secreted ADAMTS9 and decreased insulin sensitivity and signaling in human skeletal musc

115 ution may in part explain the differences in insulin sensitivity and the disproportionate burden of t

116 n with beta1/beta3 inhibition increases both insulin sensitivity and whole-body glucose utilization i

117 nd GSIS were less than in controls; however, insulin sensitivity and whole-body GUR were not differen

118 re not previously known to regulate systemic insulin sensitivity and/or energy balance.

119 ssociated with increased adiposity, improved insulin sensitivity, and a lower prevalence of diabetes.

120 o quantify hepatic and peripheral clearance, insulin sensitivity, and beta-cell function (disposition

121 the relationship between insulin clearance, insulin sensitivity, and beta-cell function and the long

122 tant functions: promoting insulin secretion, insulin sensitivity, and beta-cell mass, while inhibitin

123 of trained mice improves glucose tolerance, insulin sensitivity, and decreases plasma levels of trig

124 ome was 6-month change in insulin secretion, insulin sensitivity, and disposition index.

125 by lower body weight and body fat, improved insulin sensitivity, and enhanced energy expenditure.

126 Lipins play important roles in adipogenesis, insulin sensitivity, and gene regulation, and mutations

127 e energy expenditure, substrate utilization, insulin sensitivity, and glucose tolerance were all elev

128 thropometry, measures of beta-cell function, insulin sensitivity, and lifestyle) data comprised the k

129 y and hypertrophied adipocytes but preserved insulin sensitivity, and males exhibited physiologic cha

130 ensitivity measures, biological mediators of insulin sensitivity, and measures of fasting glucose met

131 with low dairy intake on glucose metabolism, insulin sensitivity, and metabolic flexibility in overwe

132 een circadian clocks, glucose metabolism and insulin sensitivity, and present current evidence for a

133 APOM expression with metabolic syndrome and insulin sensitivity, and study the regulation of its exp

134 sp8 in governing hypothalamic Jnk signaling, insulin sensitivity, and systemic glucose tolerance was

135 cle, adipose tissue and liver regulate local insulin sensitivity, and the peripheral clock in the pan

136 od intake, energy expenditure and whole-body insulin sensitivity, and these actions are further fine-

137 ularization and function of adipose tissues, insulin sensitivity, and whole-body metabolic state.

138 Loss of muscle mass and insulin sensitivity are common phenotypic traits of immo

139 sociated with improved glucose tolerance and insulin sensitivity as well as with impaired fasting glu

140 reduction of both glucose clearance rate and insulin sensitivity, as early as two months of age.

141 he primary outcome was the change in hepatic insulin sensitivity, assessed by infusion of insulin at

142 th oestradiol displayed increased whole-body insulin sensitivity, associated with reduction in ectopi

143 partial pressure (pO2); liver and whole-body insulin sensitivity; AT expression of genes and pathways

144 Secondary outcomes were changes in muscle insulin sensitivity, beta-cell function, and 24-hour pla

145 ssessed by intention to treat, was change in insulin sensitivity between 0 and 6 weeks as measured by

146 mpared with CON:CR, eTRF improved whole-body insulin sensitivity [between-group difference (95% CI):

147 Exercise training improved insulin sensitivity beyond surgery alone (e.g., Matsuda

148 of pro-inflammatory cytokines and reinstates insulin sensitivity both in in vitro and in vivo diet-in

149 ly produced acyl-ghrelin not only influences insulin sensitivity but also is permissive for the norma

150 sed whole-body glucose utilization rates and insulin sensitivity but had no effect on isolated islet

151 ted ADRbeta2 stimulation improved whole-body insulin sensitivity but minimally affected defects in GS

152 formin-treated animals had restored systemic insulin sensitivity but remained glucose intolerant as d

153 rsely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hou

154 and RYGB had an additive effect on enhancing insulin sensitivity, but surgery alone did not resolve i

155 cell function (insulin secretion relative to insulin sensitivity) by 1.83 units (95% CI, 1.22 to 2.44

156 The placenta participates in maternal insulin sensitivity changes during pregnancy; however, m

157 rginal, improvements in revised Quantitative Insulin Sensitivity Check Index (QUICKI) (0.004) and pla

158 Impaired tissue insulin sensitivity coincided with reduced insulin recep

159 r concentrations of triglycerides, and lower insulin sensitivity compared with early eaters (all P <0

160 fee consumption did not significantly change insulin sensitivity compared with placebo (percentage me

161 4), with patients and siblings showing lower insulin sensitivity, compared to controls (P = 0.006 and

162 e phosphorylation and glycolysis, increasing insulin sensitivity, correcting mitochondrial dysfunctio

163 Instead, we show that impaired insulin sensitivity correlated with circulating levels o

164 Using gene expression, genotype, and insulin sensitivity data from the African American Genet

165 In SR, whole-body insulin sensitivity decreased ~13% during insufficient s

166 , and in WR, whole-body, hepatic, and muscle insulin sensitivity decreased ~9%-27% during recurrent i

167 develop impairments in glucose tolerance and insulin sensitivity despite development of a high bone m

168 n in people with obesity who did not improve insulin sensitivity despite marked (~20%) weight loss.

169 creased insulin secretion by 35% even though insulin sensitivity did not change.

170 der clamp conditions, whole-body and hepatic insulin sensitivity did not differ between diets.

171 Decline in insulin sensitivity due to dysfunction of adipose tissue

172 Insulin sensitivity during hyperglycemic clamp declined

173 dian timing, energy intake, weight gain, and insulin sensitivity during sustained insufficient sleep

174 ice exhibited improved glucose tolerance and insulin sensitivity, effects associated with lower AT in

175 we assessed the accuracy of the single-point insulin sensitivity estimator (SPISE) to diagnose cardio

176 The decline in insulin sensitivity, even in the absence of an impairmen

177 ction as an insulin antagonist with elevated insulin sensitivity evident in humans and mice lacking a

178 Muscle insulin sensitivity for stimulating glucose uptake is en

179 m a glucose-potentiated arginine (GPA) test, insulin sensitivity from a hyperinsulinemic-euglycemic (

180 enous glucose tolerance test revealed higher insulin sensitivity, glucose effectiveness, and insulin

181 However, it significantly impaired insulin sensitivity, glycemic control, lipid metabolism,

182 explain the mechanisms leading to decreased insulin sensitivity has been very limited.

183 hip between TRLP subfractions and whole-body insulin sensitivity, hepatic and visceral fat, and SCD-1

184 se/muscle contraction can enhance whole-body insulin sensitivity; however, in humans the range of imp

185 Glucose tolerance and insulin sensitivity improved (P < 0.001), and body and v

186 Moreover, insulin sensitivity improved in NMES vs. sham (average b

187 Insulin sensitivity improved, but the insulinotropic eff

188 statin during the acute phase of MI reduces insulin sensitivity in a dose-dependent manner.

189 tocrine manner but also regulates peripheral insulin sensitivity in a paracrine manner through circul

190 KBTBD2 maintains insulin sensitivity in adipocytes by restricting the abu

191 and regulates triglyceride accumulation and insulin sensitivity in adipocytes.

192 d may be therapeutically targeted to improve insulin sensitivity in aged WAT.

193 n reducing body weight, but not on improving insulin sensitivity in both diet-induced obese and lean

194 the regulation of metabolic homeostasis and insulin sensitivity in both human and rodent studies.

195 e contribution of hyperglycemia by comparing insulin sensitivity in control and GCK-MODY and the cont

196 cytokine interferon-gamma activity enhanced insulin sensitivity in diet-induced obesity.

197 r improved CL-induced glucose metabolism and insulin sensitivity in female obese mice, but did not af

198 uclear ERalpha alters the central control of insulin sensitivity in females and predominantly impairs

199 y, we examined insulin action by quantifying insulin sensitivity in first-episode psychosis (FEP) pat

200 e exercise response in relation to improving insulin sensitivity in human skeletal muscle.

201 pecies, and localization of lipids influence insulin sensitivity in humans.

202 rated an iPSC library across the spectrum of insulin sensitivity in humans.

203 t glycemia and improve glucose tolerance and insulin sensitivity in insulin-resistant aged chow- and

204 glucose homeostasis, insulin secretion, and insulin sensitivity in male and female mice expressing e

205 ation of FAHFA levels, glucose tolerance, or insulin sensitivity in mice, indicating that therapeutic

206 s insulin action on metabolism, and improves insulin sensitivity in mice.

207 nd exercise to enhance muscle and whole-body insulin sensitivity in mice.

208 cemic clamp studies show that BAM15 improves insulin sensitivity in multiple tissue types.

209 The enhanced insulin sensitivity in muscle from wild-type mice was as

210 as observed by decreased Irs1 expression and insulin sensitivity in muscle-specific APC- and TAZ-doub

211 its inhibitor improves, muscle strength and insulin sensitivity in osteoporotic mice and humans.

212 ition of CB1R improves insulin secretion and insulin sensitivity in pancreatic beta-cells and hepatoc

213 nfluence of AT oxygenation on AT biology and insulin sensitivity in people.METHODSWe evaluated subcut

214 stribution, reduce inflammation, and improve insulin sensitivity in PLHIV.

215 entally linked to the regulation of maternal insulin sensitivity in pregnancy.

216 her TBC1D4 is necessary for enhancing muscle insulin sensitivity in response to AICAR and contraction

217 no statistically significant improvements in insulin sensitivity in the FMT group compared to the pla

218 nally, whereas weight loss improved systemic insulin sensitivity in the intervention group, SAT displ

219 show that GPR55-null mice display decreased insulin sensitivity in these tissues, as evidenced by re

220 ly, metformin, but not nec-1, improved brain insulin sensitivity in those rats.

221 ed neuronal insulin-signaling activities and insulin sensitivity in vitro and in vivo.

222 a role of local PVAT in regulating IMVR and insulin sensitivity in vivo is lacking.

223 mechanisms by which PAHSAs enhanced hepatic insulin sensitivity included direct and indirect actions

224 methylation may causally influence maternal insulin sensitivity, including the maternally imprinted

225 d -3.28 (-5.55, -1.00) mm Hg, respectively]; insulin sensitivity increased at 3 and 6 mo and fasting

226 According to EHC, insulin sensitivity increased by 20 +/- 60% in S10 and d

227 er, where it has been implicated in impaired insulin sensitivity, increased fat accumulation and dysl

228 tion between AT APOM expression and systemic insulin sensitivity, independently of fat mass and plasm

229 ance, or both [22 women, 17 men; mean +/- SD insulin sensitivity index (ISI): 2.7 +/- 1.3; body mass

230 at 2 years in C-reactive protein (p=0.012), insulin sensitivity index (p<0.0001), and metabolic synd

231 very small TRLPs negatively correlated with insulin sensitivity index and positively correlated with

232 d by proton magnetic resonance spectroscopy, insulin sensitivity index calculated by minimal modeling

233 Hepatic fat, insulin sensitivity index, and SCD-1 were similar in bla

234 sm have been limited by the use of surrogate insulin sensitivity indices, small sample sizes, lack of

235 with obesity who were matched on multiorgan insulin sensitivity (inhibition of adipose tissue lipoly

236 n myoblasts, the statin-mediated decrease in insulin sensitivity is counteracted by the expression of

237 Insulin sensitivity is greater in premenopausal women co

238 ar effects, suggesting that improved hepatic insulin sensitivity is the primary contributor to the be

239 Impaired insulin sensitivity (IS) and beta-cell dysfunction resul

240 -) males fed an HFD showed strongly improved insulin sensitivity (IS).

241 ted the differentiation process and impaired insulin sensitivity, lipid storage capacity, and lipolys

242 prove systemic glucose and lipid metabolism, insulin sensitivity, liver steatosis, or adipose inflamm

243 t mice have decreased adiposity and maintain insulin sensitivity, low hepatic fat deposition and peri

244 ion, diabetes, insulin resistance, decreased insulin sensitivity, low high-density lipoprotein and el

245 Insulin sensitivity (M-value) was determined using a hyp

246 uria, renal plasma flow (RPF), fat mass, and insulin sensitivity (M/I).

247 4 in adipose tissue and muscle in whole-body insulin sensitivity, making tissue-specific GLUT4-overex

248 sed glucose and insulin measures to estimate insulin sensitivity (Matsuda index).

249 Insulin sensitivity may have a genetic basis in African

250 rence -446 [95% CI -3184 to 2292], p=0.748), insulin sensitivity (mean difference -0.45 [95% CI -1.34

251 ce interval [CI], -3184 to 2292; P = 0.748), insulin sensitivity (mean difference, -0.45; 95% CI, -1.

252 econdary outcomes included other clamp-based insulin sensitivity measures, biological mediators of in

253 were rigorously stratified by adiposity and insulin sensitivity: metabolically healthy lean (MHL; n

254 s, white adipose tissue (WAT) lipolysis, and insulin sensitivity.METHODSWe treated 14 healthy women o

255 te the effects of 6 wk NR supplementation on insulin sensitivity, mitochondrial function, and other m

256 However, no effects of NR were found on insulin sensitivity, mitochondrial function, hepatic and

257 pite promising effects on metabolic rate and insulin sensitivity, no convincing evidence for weight-l

258 lucose and lipid concentration, and improved insulin sensitivity of maternal mice.

259 ncing of expression of TRB3, did not restore insulin sensitivity or rescue processing of newly synthe

260 moglobin A1c levels (P = 0.01), and improved insulin sensitivity (P = 0.03) and beta cell function (P

261 ng increased VO2peak (P < 0.001), whole-body insulin sensitivity (P = 0.033) and flow-mediated dilata

262 co-expression architecture uncovered several insulin sensitivity-relevant gene sub-networks, and pred

263 associations with body fat distribution and insulin sensitivity (S(I)).

264 Insulin sensitivity (SI(clamp)) was studied using hyperi

265 glucose, acute insulin secretion (AIR), and insulin sensitivity (Si) were similar between groups.

266 Insulin sensitivity significantly differed among groups

267 sed apoptosis in pregnancy, without altering insulin sensitivity, suggesting that raised bile acids a

268 ese lipids appear to be more negative toward insulin sensitivity than others.

269 kine targeting muscle glucose metabolism and insulin sensitivity through a low-density lipoprotein re

270 Exercise/exercise training can enhance insulin sensitivity through adaptations in skeletal musc

271 ds, it may also contribute to improvement in insulin sensitivity through PPAR-alpha/gamma agonism, wh

272 homeostasis, hypertension, nociception, and insulin sensitivity through the metabolism of epoxy-fatt

273 e maintained a similar glucose tolerance and insulin sensitivity up to 6 months; however, by 6 months

274 orting previous studies suggesting increased insulin sensitivity upon ghrelin deletion.

275 The primary outcome of the study was insulin sensitivity, using the Matsuda index.

276 y, miR-26a in beta cells enhances peripheral insulin sensitivity via exosomes.

277 ) were characterized as "positive controls." Insulin sensitivity was analyzed by a 2-step hyperinsuli

278 Insulin sensitivity was assessed 48 h after training usi

279 Insulin sensitivity was assessed by oral glucose toleran

280 Liver and whole-body insulin sensitivity was assessed using the hyperinsuline

281 The enhanced hepatic insulin sensitivity was associated with increased insuli

282 Insulin sensitivity was defined based on the median of i

283 Skeletal muscle insulin sensitivity was determined using a hyperinsuline

284 Insulin sensitivity was linearly correlated with whole-b

285 Insulin sensitivity was not affected after 6 mo of resve

286 le with obesity than lean people even though insulin sensitivity was not different between groups.

287 Insulin sensitivity was quantified using the oral minima

288 -h glucose infusion on insulin secretion and insulin sensitivity was similar in subjects with and wit

289 After 6 mo of resveratrol supplementation, insulin sensitivity was unaffected in the resveratrol ar

290 xidative stress, mitochondrial function, and insulin sensitivity were assessed in human proliferating

291 oncentrations, and both liver and whole-body insulin sensitivity were determined in individuals who w

292 ed obese mice systemic glucose tolerance and insulin sensitivity were improved in PU.1 AKO mice and c

293 had impaired systemic glucose tolerance and insulin sensitivity when exposed to high-fat diet (HFD).

294 antly impaired glucose tolerance and reduced insulin sensitivity when maintained on an obesogenic die

295 are indications that glucose metabolism and insulin sensitivity, which are generally disturbed in ov

296 pose tissue (WAT) is associated with reduced insulin sensitivity, which contributes to whole-body glu

297 This leads to increased hepatic insulin sensitivity with increased phosphorylation of FO

298 ption 5 (STAT5) signaling in mice results in insulin sensitivity with obesity.

299 ced obesity, improving glucose tolerance and insulin sensitivity with reduced systemic inflammation.

300 ining in mice promotes muscle adaptation and insulin sensitivity with simultaneous enhancement of aut